On January 11, 2023 CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, reported that members of its senior management team are scheduled to participate in B. Riley Securities’ 3rd Annual Oncology Conference on Wednesday, January 18, 2023, at 10:30 a.m. ET (Press release, CRISPR Therapeutics, JAN 11, 2023, View Source [SID1234626176]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A link to register to view the live webcast or replay of the event will be available on the "Events & Presentations" page in the Investors section of the Company’s website at View Source

On January 11, 2023 Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, reported that monotherapy dose escalation results of the ongoing Phase I/II trial of BT8009, a second-generation BTC targeting Nectin-4, will be presented at the 2023 American Society for Clinical Oncology (ASCO) (Free ASCO Whitepaper) Genitourinary (GU) Cancers Symposium, being held February 16-18, 2023 in San Francisco, California (Press release, Bicycle Therapeutics, JAN 11, 2023, View Source [SID1234626175]). On Tuesday, February 14, 2023 at 8:00 a.m. ET, the Company will host a conference call with BT8009 investigator Dr. Capucine Baldini (Medical Oncologist, Gustave Roussy) and Dr. Daniel Petrylak (Professor of Medicine and Genitourinary Oncology, Yale School of Medicine) to discuss the data being presented.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentation Details

Title: BT8009-100: A Phase I/II Study of a Novel Bicyclic Peptide and MMAE Conjugate BT8009 in Patients with Advanced Malignancies Associated with Nectin-4 Expression, Including Urothelial Cancer
Abstract #: 498
Presenter: Capucine Baldini, M.D., on behalf of the BT8009-100 investigators
Session Title: Poster Session B: Prostate Cancer and Urothelial Carcinoma
Date/Time: Friday, February 17, 3:30 p.m. to 5:00 p.m.; 8:15 p.m. to 9:15 p.m. ET

Conference Call Details
Bicycle Therapeutics will host a conference call and webcast on Tuesday, February 14, 2023 at 8:00 a.m. ET to review the data being presented. To access the call, please dial (866) 652-5200 (domestic) or (412) 317-6060 (international) and provide the Conference ID 10174689. A live webcast of the presentation will be available on the Investors & Media section of the Bicycle website, bicycletherapeutics.com

On January 11, 2023 Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, reported that the first patient was dosed in its Phase 1/2a monotherapy clinical trial of ATRN-119, the Company’s lead ATR inhibitor for the treatment of cancers with DDR mutations (Press release, Aprea, JAN 11, 2023, View Source [SID1234626174]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Phase 1/2a clinical trial is a multi-center, open-label, dose-escalation and expansion study designed to test ATRN-119 monotherapy in patients with advanced solid tumors harboring defined mutations in DDR pathways. The Phase 1 part of the study will assess tolerability, pharmacokinetics, recommended Phase 2 dose and analysis of patient biomarkers. The Phase 2a expansion portion of the trial is designed to further evaluate tolerability and efficacy of ATRN-119 monotherapy. ATRN-119 is structurally differentiated from other ATR inhibitors. In preclinical studies, ATRN-119 has demonstrated potent anti-proliferative activity against a variety of cancer cell lines, inhibited tumor growth in genetically defined ovarian, colon, pancreatic and prostate cancer xenograft models and has shown potential to have lower hematological toxicity than other ATR inhibitors.

"Initiating clinical evaluation of ATRN-119 marks a significant milestone in our efforts to advance the development of our growing pipeline of DDR inhibitors," said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea Therapeutics. "We are committed to developing and advancing next-generation, synthetic lethality-based therapies to address the unmet medical needs of patients with genetically defined cancers. We look forward to sharing the preliminary data from this study throughout 2023."

Principal Investigator for the trial, Dr. Fiona Simpkins, M.D. Assistant Professor of Obstetrics and Gynecology, Perelman School of Medicine at the University of Pennsylvania, added: "Mutations in DDR pathways are a hallmark of many aggressive cancers and inhibition of ATR is a promising therapeutic approach to selectively target and exploit the genetic vulnerabilities of tumors with these mutations. The initiation of this Phase 1 trial represents an important step in the clinical evaluation of ATR as a target for cancer therapy."

On January 10, 2023 Atavistik Bio, a biotechnology company focused on revolutionizing the discovery of new allosteric protein-metabolite interactions to develop novel small molecule drugs for cancer, inborn errors of metabolism and other serious diseases, reported that it has entered into a collaboration agreement with Plex Research, a company providing a novel artificial intelligence (AI)-powered drug discovery platform (Press release, Atavistik Bio, JAN 10, 2023, View Source [SID1234647392]). Atavistik Bio’s incorporation of Plex Research’s technology will enrich the informatics capabilities of its Atavistik Metabolite Protein Screening (AMPS) platform and accelerate its drug discovery pipeline.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Atavistik Bio’s scalable AMPS platform combines an extensive and continually expanding protein-metabolite database map ("the Interactome"), along with advanced informatics tools, deep expertise in chemistry, and computationally rich structure-based design to systematically identify and understand the role of protein-metabolite interactions across important biological and disease-relevant pathways to inform small molecule drug discovery.

Under the collaboration, Atavistik Bio will enhance its proprietary Interactome map with Plex Research’s cloud-based AI-powered drug discovery search engine of large and disparate data sources to reveal hidden connections between related metabolites and ligands, pathways, biomarkers, and disease-relevant biology. The integration of Atavistik Bio’s AMPS data with Plex Research’s platform will create a unique and customizable data analysis engine to rapidly enable novel insights for drug discovery.

"Allosteric interactions, which we know can present novel druggable nodes for intractable targets, historically have been difficult to discover. Using our AMPS platform, we are able to systematically and rapidly interrogate protein-metabolite interactions to reveal new, disease-relevant allosteric binding sites," said Marion Dorsch, Ph.D., Atavistik Bio’s President and Chief Scientific Officer. "Fusing the enterprise-level capability of Plex’s access to large public databases with Atavistik’s proprietary data infrastructure has the potential to significantly augment the power of our AMPS platform and accelerate our efforts to drive the discovery of novel therapeutics for unmet patient needs."

"Atavistik’s platform creates opportunities to drug proteins in new ways by uncovering previously unknown regulatory sites with potentially important roles in disease," said Doug Selinger, President and CEO of Plex Research. "The breadth and depth of the Plex platform will provide important context for Atavistik’s AMPS data, which will enable better characterization of putative protein regulatory sites, ligand binding, and potential impacts on disease processes. The synergies between our technology platforms are compelling, and we’re excited to see where it will take us."

On January 10, 2023 Prestige Biopharma Limited, a Singapore-based biopharmaceutical company specializing in antibody drug development, reported that the company has obtained a patent in Korea for ‘Novel CTHRC1-specific antibodies and the use thereof’ (PBP1710) designed by its Innovative Discovery Centre (IDC) to treat solid cancer including pancreatic cancer (Press release, Prestige BioPharma, JAN 10, 2023, View Source [SID1234626262]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Solid tumors including pancreatic cancer, express abnormally high levels of CTHRC1 (collagen triple helix repeat containing 1), a protein that facilitates cancer cell migration and growth. PBP1710 specifically binds to CTHRC1 and exerts anti-metastasis and anti-tumor growth effects.

According to IDC, PBP1710 has shown remarkable research results on a cellular level, reducing cancer cell migration and invasion by approximately 45% in solid cancer such as pancreatic cancer, ovarian cancer, breast cancer and colorectal cancer. In addition, animal testing has shown PBP1710’ effect to inhibit cancer cell proliferation is equivalent to that of current primary cancer treatment in the market.

A source from Prestige Biopharma stated: "This patent registration is significant in that we are preoccupying the technological advantage on the anti-CTHRC1 antibodies that can be used as a wide range of solid cancer treatments. Considering that CTHRC1 is highly distributed in many different types of cancer, the successful development of PBP1710 as a next-generation antibody drug is expected to greatly contribute to the improvement of cancer patient treatment and survival, particularly in combination with other cancer treatments."

PBP1710 is currently under review for patent registration in 21 other countries and regions including the US, Europe, Japan, and China. Meanwhile, Prestige Biopharma’s first-in-class antibody pipeline for includes PBP1710 (Anti-CTHRC1) and PBP1510 (Anti-PAUF) for pancreatic cancer treatment which is currently in phase 1/2a clinical trial.

CTHRC1 promotes cancer cell migration through activation of the Wnt5 signaling pathway by forming CTHRC1-Wnt5-Fzd2/Ror2 complexes on cancer cells.

CTHRC1 stimulates formation of blood vessels (angiogenesis) in tumor tissues by upregulating the secretion of Ang-2, a Tie2 ligand, from endothelial cells. Activation of Ang-2/Tie2 axis in monocytes is critical in tumor angiogenesis. PBP1710 specifically binds to CTHRC1 and exerts anti-metastasis and anti-tumor growth effects.